Atossa Therapeutics will host a conference call on March 25, 2025, to discuss its 2024 financial results.
Quiver AI Summary
Atossa Therapeutics, Inc. has announced a conference call and live audio webcast scheduled for March 25, 2025, at 8:30 a.m. ET, to discuss the company's corporate and financial results for the fourth quarter and full-year 2024. Interested parties can access the webcast through the investor relations section of Atossa's website, or participate by phone using designated U.S. and international numbers. The company, a clinical-stage biopharmaceutical firm focused on innovative breast cancer treatments, is developing its lead product candidate, (Z)-endoxifen, for various breast cancer applications. After the call, a replay will be available on the company's website for 30 days.
Potential Positives
- Atossa Therapeutics is set to provide a corporate and financial update, indicating transparency and communication with investors regarding its performance and progress.
- The announcement highlights the company's focus on innovative medicine for breast cancer, showcasing its commitment to address significant medical needs in a critical area of healthcare.
- The lead product candidate, (Z)-endoxifen, is positioned for comprehensive use in various breast cancer settings, suggesting a broad potential market and application for the drug.
- The availability of the conference call and webcast for a replay enhances accessibility for shareholders and stakeholders, supporting broader engagement with the company's strategies and outcomes.
Potential Negatives
- None
FAQ
What is Atossa Therapeutics' conference call about?
Atossa Therapeutics' conference call will discuss the corporate and financial results for Q4 and full-year 2024.
When is the Atossa Therapeutics conference call scheduled?
The conference call is scheduled for Tuesday, March 25, 2025, at 8:30 a.m. ET.
How can I access the Atossa Therapeutics conference call?
Listeners can access the call via telephone or live audio webcast on the company's website.
What is Atossa Therapeutics' lead product candidate?
Atossa’s lead product candidate is (Z)-endoxifen, a potent treatment option for breast cancer across various stages.
Where can I find the conference call replay?
A replay of the conference call will be available for 30 days on the investor relations section of the company's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ATOS Hedge Fund Activity
We have seen 35 institutional investors add shares of $ATOS stock to their portfolio, and 35 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 1,053,910 shares (+1488.7%) to their portfolio in Q4 2024, for an estimated $994,996
- CITADEL ADVISORS LLC added 265,921 shares (+164.3%) to their portfolio in Q4 2024, for an estimated $251,056
- RENAISSANCE TECHNOLOGIES LLC added 247,562 shares (+18.9%) to their portfolio in Q4 2024, for an estimated $233,723
- JPMORGAN CHASE & CO added 211,654 shares (+141.4%) to their portfolio in Q4 2024, for an estimated $199,822
- VIRTU FINANCIAL LLC added 157,549 shares (+311.1%) to their portfolio in Q4 2024, for an estimated $148,742
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 154,404 shares (+215.1%) to their portfolio in Q4 2024, for an estimated $145,772
- MARINER, LLC removed 105,910 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $160,983
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024.
The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Atossa Therapeutics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at www.atossatherapeutics.com .
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including metastatic, neoadjuvant, adjuvant, and prevention settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit
atossatherapeutics.com
.
Contact
Michael Parks, VP Investor and Public Relations
484-356-7105
[email protected]
